New York, April 22, 2021 (GLOBE NEWSWIRE) – Reportlinker.com Announces the Release of the Report, “Global Telmisartan Market By Indication, Distribution Channel, Regional Outlook, Industry Analysis Report and Forecast, 2020-2026” – https: //www.reportlinker .com / p06064821 /? utm_source = GNW
Telmisartan is available in several generic forms and under the trade name Micardis. Telmisartan also has side effects such as cough, dizziness, sinus pain, drowsiness, and others.
Aspects such as rising cases of high blood pressure, the incidence of chronic diseases such as diabetes, and the increasing geriatric population would fuel the growth of the global telmisartan market. In addition, a growing number of Abbreviated New Drug Application (ANDA) approvals for the manufacture of generic telmisartan tablets would open new growth paths for the global telmisartan market.
Some of the factors responsible for the growth of the Telmisartan market are rising cases of high blood pressure (hypertension), increasing geriatric populations, and an increase in supportive government initiatives to raise awareness of blood pressure disorders. Additionally, several factors would also complement the Telmisartan Market such as: B. increasing market approvals for generic forms of telmisartan, increasing sedentary lifestyle and increasing incidence of chronic diseases such as kidneys and diabetes.
The World Health Organization (WHO) announced COVID-19 a global public health emergency on January 30, 2020. COVID-19 has severely hit approximately 210 nations around the world. Companies that make and sell Telmisartan tablets have been hard hit by COVID-19 to some extent as several COVID-19 affected countries closed and the number of healthcare workers increased during the outbreak of the COVID-19 pandemic which leads to the storage of the supply.
Based on the indication, the market is divided into Hypertension and Cardiovascular Risk Reduction. Currently, the Hypertension segment has reached the maximum revenue share of the market in 2019 and would maintain a similar trend over the forecast period. Various determinants, including rising cases of high blood pressure, increasing demand for antihypertensive drugs, and increasing awareness of high blood pressure and its management through global campaigns, would drive the growth of the segment.
Sales channel outlook
Based on the sales channel, the market is divided into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Due to the distribution channels, the market is divided into drugstores and retail pharmacies, hospital pharmacies and online pharmacies. The hospital pharmacy segment would generate a significant share of sales in the forecast period due to the increasing number of hospital pharmacies worldwide and the wide availability of hospital pharmacies. In addition, the growth of the segment is due to the growing number of high blood pressure patients in the hospital and the development of the structure of hospital pharmacies in developing countries such as China and India.
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, and Latin America, the Middle East and Africa. North America would become the leading region in the global telmisartan market. This is due to the various product launches in the United States. For example, Mylan Inc., an international pharmaceutical company, introduced Telmisartan tablets USP, 20 mg, 40 mg, and 80 mg, which are the generic form of Micardis tablets from Boehringer Ingelheim, in July 2014 and received final approval from US Food and Drug Administration Drug Administration (FDA) for the acronym for new drugs (ANDA).
The market research report deals with the analysis of the key market players. Key companies featured in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan NV, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd . and Cadila Healthcare Ltd. (Zydus Cadila).
Strategies in the Telmisartan Market
Jun-2020: Cipla partners with Boehringer Ingelheim India. As part of this partnership, the companies wanted to jointly market three new oral antidiabetic drugs, Oboravo (empagliflozin), Oboravo Met (empagliflozin + metformin) and Tiptengio (empagliflozin + linagliptin). Empagliflozin is approved for glucose control in patients with type 2 diabetes. It is also approved to reduce the risk of cardiovascular death in patients with type 2 diabetes and cardiovascular disease.
February 2019: Cipla partners with Wellthy Therapeutics Private Limited. The partnership aimed to provide a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology.
February 2019: Teva Pharmaceutical launches ALYQ, a generic version of ADCIRCA1 (tadalafil) tablets, 20 mg in the United States. It is a phosphodiesterase 5 (PDE5) inhibitor that is recommended for the treatment of pulmonary arterial hypertension (PAH) (WHO group 1) to improve exercise ability.
Oct-2018: Boehringer Ingelheim received approval for SEMINTRA 10 mg / ml oral solution from the US Food & Drug Administration. The SEMINTRA solution is used to control systemic hypertension in cats, a common condition in older cats. It is designed to make it easier for cat owners and veterinarians to manage hypertension in cats. SEMINTRA is the only FDA cleared solution for hypertension in cats in an easy-to-administer formulation.
Oct-2018: Cipla has received approval from the U.S. Department of Health to market metoprolol tablets. These tablets are used to cure high blood pressure and various heart diseases. Metoprolol succinate prolonged-release tablets are used to treat high blood pressure, lower blood pressure and angina pectoris.
September 2018: Sun Pharmaceutical Industries Ltd. Received New Drug Application (NDA) approval from the US Food and Drug Administration (USFDA) for XELPROSTM 0.005%. It helps reduce the increased pressure in the eye in patients with open-angle glaucoma or ocular hypertension. The approval received is from Sun Pharma’s Halol facility.
August 2018: Mylan NV launches Tadalafil Tablets USP, 20 mg in the USA. It was the first generic version of the reference list drug Eli Lilly and Company’s Adcirca. Mylan Pharmaceuticals has received FDA approval for the New Drugs Abbreviation (ANDA). It was also marketed exclusively for this product, which is used in the treatment of pulmonary arterial hypertension to improve physical performance, for 180 days.
August 2018: Sun Pharmaceutical releases Kapspargo extended-release sprinkle capsules in the United States. It helps treat high blood pressure (to lower blood pressure), angina (chest pain), and heart failure (to minimize the risk of cardiovascular mortality and hospitalization for heart failure in patients with heart failure).
Oct-2017: Boehringer Ingelheim extends its agreement with Astellas Pharma, a Japanese multinational pharmaceutical company. The expanded agreement focused on the sale of telmisartan (Micardis family) in Japan.
Aug-2017: Zydus Cadila received USFDA approval to commercialize Telmisartan and Hydrochlorothiazide Tablets USP in dosages of 40 mg / 12.5 mg, 80 mg / 12.5 mg, and 80 mg / 25 mg. Telmisartan and hydrochlorothiazide tablets are used to treat high blood pressure.
May 2017: Aurobindo Pharma received US Food and Drug Administration (FDA) approval for its generic version of olmesartan medoxomil and hydrochlorothiazide tablets in doses of 20 mg / 12.5 mg, 40 mg / 12.5 mg and 40 mg / 25 mg. These tablets are used to treat high blood pressure to lower blood pressure.
January 2017: Agile Pharma, a subsidiary of Aurobindo Pharma, has completed the acquisition of Generis Farmacêutica from Magnum Capital Partners. The acquisition strengthened the Aurobindo Group’s position on the pharmaceutical market in Portugal with 271 products in its portfolio.
November 2016: Teva Pharmaceutical received FDA approval for Tribenzor 1 generic tablets in the United States. Teva also received approval and launched Azor2 generic tablets in the United States. These tablets enhance Teva’s antihypertensive portfolio.
Scope of study
Market Segments Covered In The Report:
• Reduction of cardiovascular risk
By distribution channel
• Hospital pharmacies
• Drug stores and retail pharmacies
• Online pharmacies
According to geography
• North America
o Rest of North America
o Great Britain
o Rest of Europe
• Asia Pacific
o South Korea
o Rest of Asia Pacific
of Saudi Arabia
o South Africa
o rest of LAMEA
• Abbott Laboratories
• Aurobindo Pharma Limited
• Boehringer Ingelheim International GmbH
• Cipla Limited
• GlaxoSmithKline PLC (GSK)
• Mylan NV
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Cadila Healthcare Ltd. (Zydus Cadila)
• Full coverage
• Highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Secure support for post-sales research with 10% free customization
Read the full report: https://www.reportlinker.com/p06064821/?utm_source=GNW
Via report linker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you can get all the market research you need in one place, instantly.